YOLFTbeta
Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

ARWR · NASDAQ · Healthcare / Biotechnology

47.78USD+0.63 (+1.34%)

Price History

Full chart

Market Stats

Previous Close47.15
Open47.68
Day Range44.52 – 48.29
52-Week Range37.06 – 95.49
Volume3.11M
Market Cap6.94B
P/E (TTM)0.00
Forward P/E111.11
EPS-2.28
Dividend Yield0.00%
Beta1.37
50-Day Avg66.91
200-Day Avg71.55

About

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Christopher R. Anzalone Ph.D.
  • Employees711
  • Headquarters177 East Colorado Boulevard, Pasadena, CA, United States, 91105, USA
  • Websitehttps://arrowheadpharma.com

Leadership

  • Dr. Christopher R. Anzalone Ph.D.Chairman, CEO & President · b. 1969
  • Mr. Daniel J. ApelChief Financial Officer · b. 1966
  • Mr. Patrick O'Brien J.D., PharmDCOO & Secretary · b. 1964
  • Dr. James C. Hamilton M.D., MBAChief Medical Officer and Head of R&D · b. 1979
  • Dr. Mark M. Davis Ph.D.Founder and Founder & Director of Insert Therapeutics Inc & Calando
  • Dr. Tao Pei Ph.D.Chief Scientific Officer
  • Dr. Vincent Anzalone CFAHead of Investor Relations & VP
  • Mr. Howard LovyDirector of Communications
  • Dr. Bruce D. Given M.D.Chief Medical Scientist · b. 1954
  • Dr. Mark SeefeldHead of Toxicology & VP · b. 1954

Financials

Income Statement

Currency: USD1997-09-301998-09-301999-09-302000-09-302001-09-302002-09-302003-09-302004-09-302005-09-302006-09-302007-09-302008-09-302009-09-302010-09-302011-09-302012-09-302013-09-302014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Revenue76.59K60.38K37.00K24.88K9.31K2.27K-196.31K590.68K595.46K1.21M1.30M3.76M620.10K296.14K146.88K290.27K175.00K382.00K158.33K31.41M16.14M168.80M87.99M138.29M243.23M240.74M3.55M829.45M
Growth (%)--21.17%-38.72%-32.76%-62.57%-75.67%--+200.90%+0.81%+102.87%+7.88%+188.38%-83.50%-52.24%-50.40%+97.63%-39.71%+118.29%-58.55%+19736.49%-48.60%+945.67%-47.87%+57.16%+75.89%-1.03%-98.52%+23258.15%
Cost of Revenue36.97K6.67K2.85K2.09K6.30K87-74.74K644.01K7.36M11.78M14.85M9.03M4.95M267.98K1.75M3.17M3.81M81.98M82.45M63.71M67.38M---10.42M12.49M18.59M23.93M
Gross Profit39.62K53.71K34.15K22.78K3.02K2.18K-121.57K-53.32K-6.76M-10.57M-13.55M-5.26M-4.33M28.16K-1.60M-2.88M-3.63M382.00K158.33K31.41M16.14M168.80M87.99M138.29M243.23M228.24M-15.04M829.45M
Gross Margin51.73%88.95%92.29%91.58%32.38%96.16%-61.93%-9.03%-1135.71%-874.84%-1039.80%-139.91%-698.68%9.51%-1090.79%-993.16%-2076.18%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%94.81%-423.66%100.00%
Operating Expense198.24K78.00K90.36K132.02K109.28K1.42M-2.81M9.54M13.72M27.38M21.45M14.30M4.47M9.86M19.49M21.71M49.64M96.36M81.90M68.40M72.08M107.60M181.15M287.32M421.74M433.24M586.04M731.10M
Operating Income-158.62K-24.30K-56.22K-109.23K-106.27K-1.42M-94.44K-2.69M-9.59M-20.48M-37.95M-35.00M-19.56M-8.80M-9.83M-21.09M-24.59M-53.28M-95.97M-81.74M-37.00M-55.94M61.19M-93.16M-149.04M-178.51M-205.00M-601.08M98.35M
Operating Margin-207.10%-40.24%-151.94%-439.08%-1141.16%-62498.41%--1370.73%-1624.03%-3439.94%-3141.43%-2685.89%-520.47%-1419.46%-3319.48%-14358.61%-8471.29%-30443.59%-25124.08%-51627.09%-117.79%-346.52%36.25%-105.87%-107.77%-73.39%-85.16%-16927.06%11.86%
EBITDA-54.83K-15.11K-48.10K-101.61K-102.74K-1.41M-94.35K-2.62M-8.95M-19.60M-36.95M-33.87M-18.57M654.69K-9.56M-19.34M-21.53M-49.76M-93.64M-76.43M-32.31M-51.24M65.63M-87.22M-132.58M-168.09M-175.67M-561.51M164.82M
EBITDA Margin-71.59%-25.03%-130.00%-408.45%-1103.30%-62097.79%--1332.66%-1515.00%-3290.98%-3058.33%-2598.92%-494.00%105.58%-3228.99%-13167.82%-7417.27%-28433.28%-24512.50%-48272.86%-102.86%-317.41%38.88%-99.12%-95.87%-69.11%-72.97%-15812.81%19.87%
Net Income-854.53K-165.03K593.00K-137.55K-185.82K-246.21K-95.24K-2.53M-6.85M-19.00M-29.93M-27.09M-19.31M-5.77M-3.13M-21.13M-31.14M-58.63M-91.94M-81.72M-34.38M-54.45M67.97M-84.55M-140.85M-176.49M-205.28M-599.49M-1.63M
Net Income Margin-1115.73%-273.32%1602.80%-552.91%-1995.50%-10865.27%--1287.86%-1160.51%-3190.35%-2477.70%-2078.65%-513.77%-931.15%-1056.56%-14383.61%-10729.22%-33502.97%-24068.29%-51614.63%-109.46%-337.32%40.27%-96.09%-101.85%-72.56%-85.27%-16882.37%-0.20%
R&D------3.38K793.35K3.79M8.58M10.94M8.31M6.21M857.41K3.28M5.39M8.71M23.14M47.27M41.45M46.25M48.30M76.63M123.54M206.34M297.31M342.31M489.22M607.16M
R&D as % of Total Revenue-------404.14%642.20%1441.25%905.25%637.63%165.17%138.27%1106.83%3670.78%2999.19%13221.74%12373.65%26181.81%147.26%299.19%45.40%140.40%149.21%122.23%142.19%13776.85%73.20%
Interest Expense000000000000150.89K48.02M86.53M35.97M97.91K645.49M729.16M265.79M415.13M1.05B6.96B9.19B6.12M5.03M18.33M32.35M89.36M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%-0.00%0.00%0.00%0.00%0.00%4.02%7744.76%29219.39%24487.49%33.73%368853.14%190879.06%167870.25%1321.74%6495.49%4122.00%10444.70%4.43%2.07%7.61%911.07%10.77%

Balance Sheet

Currency: USD1997-09-301998-09-301999-09-302000-09-302001-09-302002-09-302003-09-302004-09-302005-09-302006-09-302007-09-302008-09-302009-09-302010-09-302011-09-302012-09-302013-09-302014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Assets107.68K84.78K82.29K65.15K46.30K63.56K1.52M11.92M29.04M34.53M29.85M17.26M7.70M12.35M15.89M16.53M37.33M182.82M132.27M128.18M104.02M111.61M349.85M522.50M710.15M691.94M765.55M1.14B1.39B
Total Liabilities2.68M2.71M1.08M1.19M1.35M1.61M96.18K689.70K1.02M2.92M3.40M4.95M2.84M4.28M3.32M7.72M11.59M16.83M22.65M33.15M23.16M16.37M105.81M60.72M301.33M273.60M478.39M948.74M881.88M
Total Equity-2.58M-2.63M-996.10K-1.13M-1.30M-1.55M1.42M9.45M26.13M30.67M26.30M12.30M4.86M9.05M12.56M11.03M27.50M166.54M110.18M95.58M81.42M95.80M244.59M461.78M408.82M398.52M271.34M185.44M466.05M
Cash1.17K1.02K1241.95K27118.49K1.36M8.55M22.47M28.02M24.12M10.09M2.02M6.85M7.51M3.38M19.11M132.51M81.21M85.37M24.84M30.13M221.80M143.58M184.43M108.00M110.89M102.69M226.55M
Total Debt1.02M1.34M565.00K563.00K559.00K633.50K---1.20M-1.54M1.23M500.00K1.55M2.34M2.30M1.02M758.34K2.73M2.53M2.33M-21.14M25.55M81.58M383.50M851.91M366.28M
Net Debt1.02M1.34M564.88K561.05K558.73K615.01K-1.36M-8.55M-22.47M-26.82M-24.12M-8.56M-793.69K-6.35M-6.90M-1.04M-16.81M-131.49M-80.46M-82.64M-22.31M-27.81M-221.80M-122.44M-158.89M-26.43M272.61M749.23M139.74M

Cash Flow

Currency: USD1997-09-301998-09-301999-09-302000-09-302001-09-302002-09-302003-09-302004-09-302005-09-302006-09-302007-09-302008-09-302009-09-302010-09-302011-09-302012-09-302013-09-302014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Operating Cash Flow4.56K56-35.22K-80.09K-81.81K-105.83K-157.60K-2.31M-9.10M-14.79M-23.87M-27.58M-15.28M-7.70M-5.39M-15.34M-19.03M-35.42M-65.71M-64.43M-23.94M-47.22M173.03M-95.80M171.31M-136.13M-153.89M-462.85M179.55M
Investing Cash Flow----742--1.68K-2.12K-359.62K2.27M-542.02K4.38M-2.57M739.13K487.59K-175.38K440.64K-9.52M-36.48M14.12M13.45M-48.64M-7.43M-47.75M-240.78M-141.68M-5.42M-96.16M-420.07M-129.29M
Financing Cash Flow-4.43K-20334.32K82.66K80.13K125.73K1.51M9.87M20.74M20.89M15.59M16.13M6.47M12.04M6.23M10.77M44.29M185.29M290.52K55.13M12.06M59.95M66.38M257.95M11.30M65.19M253.05M870.52M74.01M
Capital Expenditure00074201.68K2.12K665.47K672.76K934.52K756.37K684.11K40.24K5.41K9.67K479.71K296.88K1.72M1.97M3.86M7.92M1.42M12.00M11.95M23.57M52.78M176.74M141.47M22.67M
Free Cash Flow4.56K56-35.22K-80.83K-81.81K-107.51K-159.71K-2.98M-9.77M-15.73M-24.62M-28.27M-15.32M-7.70M-5.40M-15.82M-19.33M-37.13M-67.68M-68.29M-31.86M-48.64M161.03M-107.75M147.75M-188.91M-330.63M-604.32M156.89M
Dividends Paid--------------00000000-------
FCF to OCF100.00%100.00%100.00%100.93%100.00%101.58%101.34%128.75%107.39%106.32%103.17%102.48%100.26%100.00%100.18%103.13%101.56%104.85%103.00%105.99%133.08%103.01%93.06%112.48%86.24%138.77%214.85%130.56%87.38%
Dividend Paid to FCF--------------0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%-------

Earnings

Report DateMar 31, 1999Jun 30, 1999Dec 31, 1999Mar 31, 2000Jun 30, 2000Sep 30, 2000Dec 31, 2000Mar 31, 2001Jun 30, 2001Dec 31, 2001Mar 31, 2002Jun 30, 2002Dec 31, 2002Mar 31, 2003Jun 30, 2003Sep 30, 2003Dec 31, 2003Mar 31, 2004Jun 30, 2004Sep 30, 2004Dec 31, 2004Mar 31, 2005Jun 30, 2005Nov 30, 2005Mar 1, 2006May 31, 2006Aug 30, 2006Nov 29, 2006Feb 28, 2007Aug 29, 2007Feb 11, 2008May 28, 2008Sep 3, 2008Dec 16, 2008Feb 10, 2009May 15, 2009Aug 11, 2009Dec 23, 2009Feb 11, 2010May 13, 2010Aug 12, 2010Dec 23, 2010Feb 10, 2011May 12, 2011Aug 8, 2011Dec 20, 2011Feb 10, 2012May 8, 2012Aug 13, 2012Dec 21, 2012Feb 14, 2013May 10, 2013Aug 8, 2013Dec 18, 2013Feb 4, 2014May 6, 2014Aug 12, 2014Nov 25, 2014Feb 9, 2015May 11, 2015Aug 4, 2015Dec 14, 2015Feb 9, 2016May 10, 2016Aug 9, 2016Dec 14, 2016Feb 6, 2017May 3, 2017Aug 3, 2017Dec 12, 2017Feb 9, 2018May 8, 2018Aug 7, 2018Dec 11, 2018Feb 7, 2019May 8, 2019Aug 5, 2019Nov 25, 2019Feb 5, 2020May 7, 2020Aug 5, 2020Nov 23, 2020Feb 4, 2021May 4, 2021Aug 5, 2021Nov 22, 2021Feb 2, 2022May 10, 2022Aug 4, 2022Nov 28, 2022Feb 6, 2023May 2, 2023Aug 7, 2023Nov 29, 2023Feb 6, 2024May 9, 2024Aug 8, 2024Nov 27, 2024Feb 10, 2025May 12, 2025Aug 7, 2025Nov 25, 2025Feb 5, 2026May 7, 2026Aug 4, 2026Nov 12, 2026
EPS Estimate---------------------------------------0.55-0.41-0.45--0.19-0.23-0.20---------0.18-0.19-0.20-0.22-0.24-0.32-0.36-0.39-0.39-0.38-0.36-0.36-0.20-0.21-0.18-0.12-0.10-0.16-0.18-0.19-0.110.690.200.120.16-0.07-0.11-0.200.12-0.24-0.17-0.14-0.11-0.580.18-0.51-0.170.13-0.59-0.53-0.60-0.83-0.20-0.59-0.92-0.72-0.46-0.94-0.31-0.37-1.11-1.23-1.59
EPS Actual-3.16-32.59-8.00-6.96-7.394.51-5.16-6.43-4.02-7.79-1.25-10.85-5.56-12.91-6.5944.28-26.00-0.20-0.47-1.30-1.120.27-1.62-0.51-1.12-0.97-1.18-2.58-1.08-3.43-2.11-1.47-1.93-2.14-1.87-1.23-0.58-0.77-0.30-0.30-0.10-0.31-0.20-0.10-0.30-0.35-0.25-0.50-0.71-0.48-0.33-0.41-0.23-0.38-0.28-0.31-0.22-0.33-0.41-0.33-0.27-0.41-0.32-0.35-0.32-0.34-0.17-0.08-0.07-0.15-0.18-0.18-0.18-0.120.130.240.210.11-0.03-0.20-0.13-0.48-0.20-0.26-0.29-0.61-0.600.41-0.68-0.81-0.390.45-0.96-1.02-1.24-1.02-1.38-1.37-1.392.75-1.26-0.110.22-0.93-1.36-
Surprise--------------------------------------45.45%26.83%77.78%--5.26%56.52%-50.00%---------111.11%-47.37%-55.00%0.00%-37.50%-28.13%8.33%30.77%-5.13%15.79%2.78%11.11%-70.00%19.05%55.56%41.67%-50.00%-12.50%0.00%5.26%-9.09%-81.16%20.00%75.00%-31.25%57.14%-81.82%35.00%-500.00%16.67%-52.94%-107.14%-454.55%-3.45%127.78%-33.33%-376.47%-400.00%176.27%-81.13%-70.00%-49.40%-410.00%-133.90%-48.59%-93.06%697.83%-34.04%64.50%159.46%16.22%-10.57%-
Timing------------------------------------------After-hoursAfter-hoursAfter-hours---------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap6.94B
Enterprise Value7.59B
Trailing P/E0.00
Forward P/E111.11
PEG Ratio-1.32
Price / Sales10.36
Price / Book17.64
EPS-2.28
Book Value3.30
Revenue (TTM)669.49M
Gross Profit (TTM)669.49M
EBITDA-200.64M
Profit Margin-47.79%
Operating Margin-226.03%
Return on Equity-55.21%
Return on Assets-8.10%
Shares Outstanding140.86M
Shares Float122.45M
Beta1.37
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 15 analystsTarget 107.71
  • Strong Buy
    10
  • Buy
    4
  • Hold
    1

Ownership Breakdown

Institutions
85.35%
Insiders
3.66%
Retail / Other
10.99%

Top Institutional Holders

  • BlackRock Inc
    14.83M10.50%
  • venBio Select Advisor LLC
    11.36M8.04%
  • FMR Inc
    8.04M5.69%
  • Vanguard Portfolio Management, LLC
    6.35M4.50%
  • Vanguard Capital Management, LLC
    6.11M4.33%
  • State Street Corp
    5.69M4.03%
  • NORGES BANK
    3.90M2.76%
  • Amvescap Plc.
    3.88M2.75%
  • Geode Capital Management, LLC
    3.53M2.50%
  • Fred Alger Management, LLC
    3.30M2.34%
  • Baker Bros Advisors LP
    1.99M1.41%
  • Siren, L.L.C.
    1.72M1.21%
  • Vestal Point Capital LP
    1.57M1.11%

Top Fund Holders

  • iShares Core S&P Mid-Cap ETF
    5.08M3.59%
  • Vanguard MStar Total Stk Mkt Idx Invest
    4.27M3.02%
  • Vanguard Small Cap Index
    3.02M2.14%
  • Fidelity Growth Company Fund
    2.60M1.84%
  • State Street® SPDR® S&P® Biotech ETF
    1.92M1.36%
  • Invesco S&P MidCap Momentum ETF
    1.81M1.28%
  • Vanguard MStar Small Cap Growth Indx Inv
    1.68M1.19%

Stock Splits

  • Nov 17, 20111:10
  • Jan 15, 20041:65